HRP20100409T1 - Derivati azolopiridin-2-ona kao inhibitori fosfolipaze - Google Patents
Derivati azolopiridin-2-ona kao inhibitori fosfolipaze Download PDFInfo
- Publication number
- HRP20100409T1 HRP20100409T1 HR20100409T HRP20100409T HRP20100409T1 HR P20100409 T1 HRP20100409 T1 HR P20100409T1 HR 20100409 T HR20100409 T HR 20100409T HR P20100409 T HRP20100409 T HR P20100409T HR P20100409 T1 HRP20100409 T1 HR P20100409T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkylene
- formula
- accordance
- hydrogen
- Prior art date
Links
- ORKUYZDMEWAUEZ-UHFFFAOYSA-N pyrrolo[3,2-b]pyridin-2-one Chemical class N1=CC=CC2=NC(=O)C=C21 ORKUYZDMEWAUEZ-UHFFFAOYSA-N 0.000 title claims 3
- 102000004882 Lipase Human genes 0.000 title 1
- 108090001060 Lipase Proteins 0.000 title 1
- 239000004367 Lipase Substances 0.000 title 1
- 235000019421 lipase Nutrition 0.000 title 1
- 239000003428 phospholipase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 26
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 20
- 239000001257 hydrogen Substances 0.000 claims abstract 20
- 229910052736 halogen Inorganic materials 0.000 claims abstract 13
- 150000002367 halogens Chemical class 0.000 claims abstract 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 11
- 125000004122 cyclic group Chemical group 0.000 claims abstract 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 11
- -1 COOR3 Chemical group 0.000 claims abstract 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 9
- 150000002431 hydrogen Chemical class 0.000 claims abstract 7
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims abstract 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims abstract 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- 125000004429 atom Chemical group 0.000 claims abstract 4
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 4
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 4
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims abstract 3
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- 125000004980 cyclopropylene group Chemical group 0.000 claims abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005026762A DE102005026762A1 (de) | 2005-06-09 | 2005-06-09 | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
PCT/EP2006/005095 WO2006131231A1 (de) | 2005-06-09 | 2006-05-27 | Azolopyridin-2-on-derivate als inhibitoren von lipasen und phospholipasen |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100409T1 true HRP20100409T1 (hr) | 2010-09-30 |
Family
ID=37076291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100409T HRP20100409T1 (hr) | 2005-06-09 | 2010-07-23 | Derivati azolopiridin-2-ona kao inhibitori fosfolipaze |
Country Status (30)
Country | Link |
---|---|
US (2) | US7846943B2 (es) |
EP (1) | EP1896485B1 (es) |
JP (1) | JP2008542410A (es) |
KR (1) | KR20080019215A (es) |
CN (1) | CN101193896A (es) |
AR (1) | AR054132A1 (es) |
AT (1) | ATE468342T1 (es) |
AU (1) | AU2006257022A1 (es) |
BR (1) | BRPI0611688A2 (es) |
CA (1) | CA2610325A1 (es) |
CY (1) | CY1110213T1 (es) |
DE (2) | DE102005026762A1 (es) |
DK (1) | DK1896485T3 (es) |
ES (1) | ES2346561T3 (es) |
HR (1) | HRP20100409T1 (es) |
IL (1) | IL187730A0 (es) |
MA (1) | MA29481B1 (es) |
MX (1) | MX2007015347A (es) |
MY (1) | MY142792A (es) |
NO (1) | NO20080133L (es) |
NZ (1) | NZ564063A (es) |
PL (1) | PL1896485T3 (es) |
PT (1) | PT1896485E (es) |
RS (1) | RS51268B (es) |
RU (1) | RU2414473C2 (es) |
SI (1) | SI1896485T1 (es) |
TW (1) | TW200716653A (es) |
UY (1) | UY29593A1 (es) |
WO (1) | WO2006131231A1 (es) |
ZA (1) | ZA200709501B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006014685A1 (de) * | 2006-03-28 | 2007-10-04 | Sanofi-Aventis | Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010044441A1 (ja) | 2008-10-17 | 2010-04-22 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 |
ES2574927T3 (es) * | 2009-10-29 | 2016-06-23 | Glaxosmithkline Llc | Piridinas bicíclicas y análogos como moduladores de sirtuina |
US8754113B2 (en) | 2009-12-15 | 2014-06-17 | Shionogi & Co., Ltd. | Oxadiazole derivative having endothelial lipase inhibitory activity |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
CN114560873B (zh) * | 2021-12-27 | 2023-02-28 | 浙江日出药业有限公司 | 一种3-氯甲基-6-氯-噁唑[4,5-b]吡啶-2(3H)酮的制备方法 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3835576A1 (de) * | 1988-03-25 | 1989-10-12 | Bayer Ag | 3,7-disubstituierte benzthiazolone |
FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2663634B1 (fr) * | 1990-06-22 | 1992-09-04 | Adir | Nouvelles acyl benzoxazolinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
CN1158290C (zh) | 1996-01-17 | 2004-07-21 | 诺沃挪第克公司 | 稠合1,2,4-噻二嗪与稠合1,4-噻嗪衍生物、其制备方法及用途 |
WO1997041097A2 (en) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
BRPI9711437B8 (pt) | 1996-08-30 | 2021-05-25 | Novo Nordisk As | derivados de glp-1 |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
BR0010605A (pt) | 1999-04-28 | 2002-02-13 | Aventis Pharma Gmbh | Derivados ácidos de di-aril como ligantes de receptores ppar |
BR0010126A (pt) | 1999-04-28 | 2002-02-26 | Aventis Pharma Gmbh | Derivados de ácido tri-arìlico como ligandos receptores de ppar |
CA2371271A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
AU773505B2 (en) | 1999-06-18 | 2004-05-27 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
JP2003504082A (ja) | 1999-07-09 | 2003-02-04 | コヘージョン テクノロジーズ, インコーポレイテッド | エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法 |
BR0012752A (pt) | 1999-07-29 | 2002-04-02 | Lilly Co Eli | Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina |
ATE302754T1 (de) | 1999-09-01 | 2005-09-15 | Aventis Pharma Gmbh | Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
SK7652002A3 (en) | 1999-12-03 | 2002-11-06 | Astrazeneca Ab | Crystalline form of (s)-2-ethoxy-3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid |
PT2266665T (pt) | 2000-03-31 | 2016-07-07 | Royalty Pharma Collection Trust | Método para o melhoramento da sinalização de ilhéus na diabetes mellitus e para a sua prevenção |
IL152224A0 (en) | 2000-04-25 | 2003-05-29 | Kyorin Seiyaku Kk | Stable crystals of thiazolidinedione derivative and process for the preparation thereof |
CA2407538C (en) | 2000-04-28 | 2007-01-09 | Asahi Kasei Kabushiki Kaisha | Novel bicyclic compounds |
EP1280777B1 (en) | 2000-05-11 | 2005-11-23 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
DE50102147D1 (de) | 2000-06-09 | 2004-06-03 | Aventis Pharma Gmbh | Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
ATE349425T1 (de) | 2000-12-21 | 2007-01-15 | Sanofi Aventis Deutschland | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
EP1275653A1 (en) | 2001-07-10 | 2003-01-15 | Bayer CropScience S.A. | Oxazolopyridines and their use as fungicides |
JP4436129B2 (ja) | 2001-08-31 | 2010-03-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用 |
AU2002351731A1 (en) * | 2001-12-14 | 2003-06-30 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
DE10215908B4 (de) | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
IL164249A0 (en) | 2002-04-11 | 2005-12-18 | Aventis Pharma Gmbh | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use |
DE10225635C1 (de) | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10247680B4 (de) | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
WO2004094394A1 (en) | 2003-04-01 | 2004-11-04 | Eli Lilly And Company | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors |
EP1613608A1 (en) | 2003-04-01 | 2006-01-11 | Eli Lilly And Company | Phospholipase inhibitors |
DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
-
2005
- 2005-06-09 DE DE102005026762A patent/DE102005026762A1/de not_active Withdrawn
-
2006
- 2006-05-27 CN CNA2006800202416A patent/CN101193896A/zh active Pending
- 2006-05-27 AT AT06753937T patent/ATE468342T1/de active
- 2006-05-27 DK DK06753937.9T patent/DK1896485T3/da active
- 2006-05-27 ES ES06753937T patent/ES2346561T3/es active Active
- 2006-05-27 RS RSP-2010/0270A patent/RS51268B/sr unknown
- 2006-05-27 WO PCT/EP2006/005095 patent/WO2006131231A1/de active Application Filing
- 2006-05-27 BR BRPI0611688-4A patent/BRPI0611688A2/pt not_active IP Right Cessation
- 2006-05-27 PT PT06753937T patent/PT1896485E/pt unknown
- 2006-05-27 AU AU2006257022A patent/AU2006257022A1/en not_active Abandoned
- 2006-05-27 PL PL06753937T patent/PL1896485T3/pl unknown
- 2006-05-27 DE DE502006006986T patent/DE502006006986D1/de active Active
- 2006-05-27 RU RU2007145499/04A patent/RU2414473C2/ru not_active IP Right Cessation
- 2006-05-27 NZ NZ564063A patent/NZ564063A/en not_active IP Right Cessation
- 2006-05-27 SI SI200630748T patent/SI1896485T1/sl unknown
- 2006-05-27 JP JP2008515095A patent/JP2008542410A/ja not_active Abandoned
- 2006-05-27 KR KR1020077028710A patent/KR20080019215A/ko not_active Application Discontinuation
- 2006-05-27 CA CA002610325A patent/CA2610325A1/en not_active Abandoned
- 2006-05-27 EP EP06753937A patent/EP1896485B1/de active Active
- 2006-05-27 MX MX2007015347A patent/MX2007015347A/es active IP Right Grant
- 2006-06-07 TW TW095120135A patent/TW200716653A/zh unknown
- 2006-06-07 MY MYPI20062625A patent/MY142792A/en unknown
- 2006-06-07 AR ARP060102373A patent/AR054132A1/es not_active Application Discontinuation
- 2006-06-09 UY UY29593A patent/UY29593A1/es not_active Application Discontinuation
-
2007
- 2007-11-05 ZA ZA200700950A patent/ZA200709501B/xx unknown
- 2007-11-22 MA MA30415A patent/MA29481B1/fr unknown
- 2007-11-28 IL IL187730A patent/IL187730A0/en unknown
- 2007-12-05 US US11/950,932 patent/US7846943B2/en not_active Expired - Fee Related
-
2008
- 2008-01-08 NO NO20080133A patent/NO20080133L/no not_active Application Discontinuation
-
2010
- 2010-07-20 CY CY20101100675T patent/CY1110213T1/el unknown
- 2010-07-23 HR HR20100409T patent/HRP20100409T1/hr unknown
- 2010-10-28 US US12/914,045 patent/US20110039883A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100409T1 (hr) | Derivati azolopiridin-2-ona kao inhibitori fosfolipaze | |
JP2009511517A5 (es) | ||
RU2329044C1 (ru) | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство | |
RU2682247C2 (ru) | Новые производные пиразола | |
RU2008119435A (ru) | Производные триазолопиридина в качестве ингибиторов липаз и фосфолипаз | |
CA2934553C (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
JP7153938B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
RU2008114360A (ru) | Производные диацилиндазола как ингибиторы липаз и фосфолипаз | |
WO2009082268A2 (ru) | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
RU2317989C1 (ru) | ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
AU2021200164A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
WO2018234978A1 (en) | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | |
US10265327B2 (en) | V1A antagonists to treat phase shift sleep disorders | |
HRP20220177T1 (hr) | Heteroaril supstituirani beta-hidroksietilamini za upotrebu u liječenju hiperglikemije | |
EA201001344A1 (ru) | Азотсодержащие бициклические соединения, активные при состояниях хронической боли | |
WO2012002644A3 (en) | Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability | |
RU2007145439A (ru) | Производные бензооксазол-2-она как ингибиторы липаз и фосфолипаз | |
RU2384581C2 (ru) | ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
RU2007145476A (ru) | Производные бензотиазол-2-она как ингибиторы липаз и фосфолипаз | |
AU2011345414B2 (en) | Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for the production and use thereof | |
BR112021014402A2 (pt) | Métodos de tratamento de doença com inibidores de magl | |
WO2005099696A1 (ja) | アセチルコリンエステラーゼ阻害薬と5-置換-3-オキサジアゾリル-1,6-ナフチリジン-2(1h)-オン誘導体とを組み合わせてなる医薬 | |
US20140073591A1 (en) | Mdr method and products for treating mrsa | |
JP6010614B2 (ja) | 血清尿酸を低下させるための[1,2,4]チアジアジン1,1−ジオキサイド化合物 | |
Pascual et al. | New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists |